[1] 杨立新,张海峰,白淑芬.P53、Ki-67基因表达与膀胱癌相关性的回顾性研究[J].现代医学,2010,38(1):32-35.
[2] OLIVEIRA P A,ARANTES-RODRIGUES R,VASCONCELOS-NOBREGA C.Animal models of urinary bladder cancer and their application to novel drug discovery[J].Expert Opin Drug Discov,2014,9(5):485-503.
[3] ASANUMA H,ARAI T,SEGUCHI K,et al.Successful diagnosis of orthotopic rat superficial bladder tumor model by ultrathin cystoscopy[J].J Urol,2003,169(2):718-720.
[4] 梁国庆,陈春雷,陈伟杰,等.茶多酚治疗N-甲基亚硝基脲诱发膀胱肿瘤的实验研究[J].天津医药,2013(9):898-900.
[5] LI J,QU W,CHENG Y,et al.The inhibitory effect of intravesical fisetin against bladder cancer by induction of p53 and down-regulation of NF-kappa B pathways in a rat bladder carcinogenesis model[J].Basic Clin Pharmacol Toxicol,2014,115(4):321-329.
[6] 刘红耀,李晓东,米振国,等.N-甲基亚硝基脲的制备及其诱发膀胱肿瘤的作用[J].中华实验外科杂志,2000,17(6):548-549.
[7] 顾炜,徐耀庭,谢敏,等.N-甲基亚硝基脲诱导大鼠膀胱癌模型的动态观察[J].实验动物与比较医学,2011,31(1):28-32.
[8] FERREIRA R,OLIVEIRA P,MARTINS T,et al.Comparative proteomic analyses of urine from rat urothelial carcinoma chemically induced by exposure to N-butyl-N-(4-hydroxybutyl)-nitrosamine[J].Mol Biosyst,2015,11(6):1594-1602.
[9] VASCONCELOS-NOBREGA C,COSTA C,VALA H,et al.E-cadherin and β-catenin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in mice[J].Urol Int,2013,91:462-466.
[10] HOLMANG S,CANO M,GRENABO L,et al.Effect of indomethacin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide-induced urinary tract carcinogenesis[J].Carcinogenesis,1995,16(7):1493-1498.
[11] WU X.Biology of urothelial tumorigenesis:insights from genetically engineered mice[J].Cancer Metastasis Rev,2009,28(3-4):281-290.
[12] PENA F A D L,KANASAKI K,KANASAKI M,et al.Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma[J].J Biol Chem,2011,286(23):20778-20787.
[13] HE F,MO L,ZHENG X Y,et al.Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis[J].Cancer Res,2009,69(24):9413.
[14] FABRIS V T,LODILLINSKY C,PAMPENA M B,et al.Cytogenetic characterization of the murine bladder cancer model MB49 and the derived invasive line MB49-Ⅰ[J].Cancer Genet,2012,205(4):168-176.
[15] CHAN E,PATEL A,HESTON W,et al.Mouse orthotopic models for bladder cancer research[J].BJU Int,2009,104(9):1286-1291.
[16] GRIVAS P D,DAY K C,KARATSINIDES A,et al.Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer[J].Mol Med,2013,19(4):367-376.
[17] WANG H,ISAJI T,SATOH M,et al.Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model[J].Urology,2013,81(1):210.e11-210.e15.
[18] SMITH E B,SCHWARTZ M,KAWAMOTO H,et al.Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder[J].J Urol,2007,177(6):2347-2351.
[19] YANG X H,REN L S,WANG G P,et al.A new method of establishing orthotopic bladder transplantable tumor in mice[J].Cancer Biol Med,2012,9(4):261-265.
[20] DOBEK G L,GODBEY W T.An orthotopic model of murine bladder cancer[J].J Vis Exp,2011(48):2535.
[21] WATANABE T,SHINOHARA N,SAZAWA A,et al.An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies[J].Cancer Gene Therapy,2001,7(12):1575-1580.
[22] YU D,LEE C,CHANG S.Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64[J].J Urol,2007,177(2):738-742.
[23] MANGSBO S M,NINALGA C,ESSAND M,et al.CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity[J].J Immunother,2008,31(1):34-42.
[24] PALMEIRA C,OLIVEIRA P A,LAMEIRAS C,et al.Biological similarities between murine chemical-induced and natural human bladder carcinogenesis[J].Oncology Letters,2010,1(2):373-377(5).
[25] LU Y,LIU P,WEN W,et al.Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models[J].Am J Transl Res,2011,3(1):8-27. |
